The following is a summary of “Steroid-resistant nephrotic syndrome due to renal-limited thrombotic microangiopathy and ...

The first recipient of a gene-edited pig kidney died from cardiac causes 52 days after xenotransplantation. The world's first ...

IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their ...

Though highly effective, medications for the prevention of chronic kidney disease progression are under-utilized, emphasizing the need for better use of prognostic tools.

Genentech has shared positive data from the Phase III REGENCY trial with regulators in the US and EU. Roche’s subsidiary ...

DAVENPORT & Co LLC reduced its position in shares of argenx SE (NASDAQ:ARGX – Free Report) by 5.1% during the fourth quarter, ...

The global diabetic nephropathy market was valued at $1.9 billion in 2021, and is projected to reach $3.3 billion by 2031, growing at a CAGR of 6%. PORTLAND, OR, UNITED STATES, January 30, 2025 ...

We are excited to announce the initiation of our HORIZON Study for MZE829, a Phase 2 clinical trial with a novel, potential new medicine that could disrupt current treatment for AKD,” said Harold ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of its phase III REGENCY trial of Gazyva®/Gazyvaro® (obinutuzumab) in people with active lupus nephritis (LN) was published ...

Buying Alexion remains a “fantastic acquisition” for AstraZeneca, the Big Pharma’s CEO has said, even as the company takes a ...

Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; "Renalys Pharma") announced today that it has completed patient enrollment for its registrational Phase III clinical trial of sparsentan for the ...

The registrational Phase III study is a multicenter, open-label, single arm study in Japanese patients with IgA nephropathy, and is planned to confirm the efficacy and safety of sparsentan in ...